Targeted Immunotherapy for Autoimmune Disease

키워드

참고문헌 (130)

1. Cooper GS, "Recent insights in the epidemiology of autoimmune diseases : improved prevalence estimates and understanding of clustering of diseases", J Autoimmun, 33, pp.197~207 (2009)
2. Lagassé HA, "Recent advances in(therapeutic protein)drug development", F1000 Res, 6, pp.113~ (2017)
3. "Top drugs and pharma companies by sales in 2020"[URL]
4. Zarrin AA, "Kinase inhibition in autoimmunity and inflammation", Nat Rev Drug Discov, 20, pp.39~63 (2021)
5. Attwood MM, "Trends in kinase drug discovery : targets, indications and inhibitor design", Nat Rev Drug Discov, 20, pp.839~861 (2021)
6. Theofilopoulos AN, "The multiple pathways to autoimmunity", Nat Immunol, 18, pp.716~724 (2017)
7. Wahren-Herlenius M, "Immunopathogenic mechanisms of systemic autoimmune disease", Lancet, 382, pp.819~831 (2013)
8. Swiecki M, "The multifaceted biology of plasmacytoid dendritic cells", Nat Rev Immunol, 15, pp.471~485 (2015)
9. Ma WT, "The role of monocytes and macrophages in autoimmune diseases : a comprehensive review", Front Immunol, 10, pp.1140~ (2019)
10. Jiang J, "Type I interferons in the pathogenesis and treatment of autoimmune diseases", Clin Rev Allergy Immunol, 59, pp.248~272 (2020)
11. Zhu J, "Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors", Immunol Rev, 238, pp.247~262 (2010)
12. Caricchio R, "Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19 : a randomized clinical trial", JAMA, 326, pp.230~239 (2021)
13. Aletaha D, "Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy(SIRROUND-T) : a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study", Lancet, 389, pp.1206~1217 (2017)
14. Takeuchi T, "Sirukumab for rheumatoid arthritis : the phase III SIRROUND-D study", Ann Rheum Dis, 76, pp.2001~2008 (2017)
15. Nasonov E, "Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate:efficacy and safety results of a randomised controlled phase III study", Ann Rheum Dis (2021)[DOI]
16. Mease PJ, "The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis", Arthritis Rheumatol, 68, pp.2163~2173 (2016)
17. Zhang C, "Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder(TANGO) : an open-label, multicentre, randomised, phase 2 trial", Lancet Neurol, 19, pp.391~401 (2020)
18. Salama C, "Tocilizumab in patients hospitalized with COVID-19 pneumonia", N Engl J Med, 384, pp.20~30 (2021)
19. Rosas IO, "Tocilizumab in hospitalized patients with severe COVID-19 pneumonia", N Engl J Med, 384, pp.1503~1516 (2021)
20. Lescure FX, "Sarilumab in patients admitted to hospital with severe or critical COVID-19 : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Respir Med, 9, pp.522~532 (2021)
21. Deodhar A, "Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab : primary results of a randomized, placebocontrolled phase iii study", Arthritis Rheumatol, 73, pp.110~120 (2021)
22. Wei JC, "Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis : 16-week results from a randomised, placebo-controlled, phase 3 trial", Ann Rheum Dis, 80, pp.1014~1021 (2021)
23. Mease PJ, "Brodalumab in psoriatic arthritis : results from the randomised phase III AMVISION-1 and AMVISION-2 trials", Ann Rheum Dis, 80, pp.185~193 (2021)
24. Gordon KB, "Bimekizumab efficacy and safety in moderate to severe plaque psoriasis(BE READY) : a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial", Lancet, 397, pp.475~486 (2021)
25. Warren RB, "Bimekizumab versus adalimumab in plaque psoriasis", N Engl J Med, 385, pp.130~141 (2021)
26. Östör A, "Efficacy and safety of risankizumab for active psoriatic arthritis : 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial", Ann Rheum Dis, 81, pp.351~358 (2022)
27. Kristensen LE, "Efficacy and safety of risankizumab for active psoriatic arthritis : 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial", Ann Rheum Dis, 81, pp.225~231 (2022)
28. Werth VP, "Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris", N Engl J Med, 384, pp.2295~2305 (2021)
29. Bowman SJ, "Safety and efficacy of subcutaneous ianalumab(VAY736)in patients with primary Sjögren’s syndrome : a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial", Lancet, 399, pp.161~171 (2022)
30. Mease PJ, "Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis", Ann Rheum Dis, 76, pp.1550~1558 (2017)
31. Ruperto N, "Tofacitinib in juvenile idiopathic arthritis : a double-blind, placebocontrolled, withdrawal phase 3 randomised trial", Lancet, 398, pp.1984~1996 (2021)
32. Deodhar A, "Tofacitinib for the treatment of ankylosing spondylitis : a phase III, randomised, doubleblind, placebo-controlled study", Ann Rheum Dis, 80, pp.1004~1013 (2021)
33. Simpson EL, "Baricitinib in patients with moderate-to-severe atopic dermatitis : results from a randomized monotherapy phase 3 trial in the United States and Canada(BREEZE-AD5)", J Am Acad Dermatol, 85, pp.62~70 (2021)
34. Reich K, "Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis : a randomized clinical trial", JAMA Dermatol, 156, pp.1333~1343 (2020)
35. Sandborn WJ, "Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis", Gastroenterology, 158, pp.2139~2149 (2020)
36. Guttman-Yassky E, "Once-daily upadacitinib versus placebo in adolescents and adults with moderateto-severe atopic dermatitis(Measure Up 1 and Measure Up 2) : results from two replicate double-blind, randomised controlled phase 3 trials", Lancet, 397, pp.2151~2168 (2021)
37. Reich K, "Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis(AD Up) : results from a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 397, pp.2169~2181 (2021)
38. Feagan BG, "Filgotinib as induction and maintenance therapy for ulcerative colitis(SELECTION) : a phase 2b", 3 double-blind, randomised, placebo-controlled trial, 2021, pp.397, 2372~2384
39. Kruglov AA, "Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells", J Immunol, 187, pp.5660~5670 (2011)
40. Feldmann M, "Translating molecular insights in autoimmunity into effective therapy", Annu Rev Immunol, 27, pp.1~27 (2009)
41. Keffer J, "Transgenic mice expressing human tumour necrosis factor : a predictive genetic model of arthritis", EMBO J, 10, pp.4025~4031 (1991)
42. Atretkhany KN, "Distinct modes of TNF signaling through its two receptors in health and disease", J Leukoc Biol, 107, pp.893~905 (2020)
43. Fischer R, "Selective targeting of TNF receptors as a novel therapeutic approach", Front Cell Dev Biol, 8, pp.401~ (2020)
44. Conrad C, "TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis", Nat Commun, 9, pp.25~ (2018)
45. Talotta R, "Paradoxical expansion of Th1 and Th17 lymphocytes in rheumatoid arthritis following infliximab treatment : a possible explanation for a lack of clinical response", J Clin Immunol, 35, pp.550~557 (2015)
46. Salomon BL, "Insights into the biology and therapeutic implications of TNF and regulatory T cells", Nat Rev Rheumatol, 17, pp.487~504 (2021)
47. Dinarello CA, "The IL-1 family of cytokines and receptors in rheumatic diseases", Nat Rev Rheumatol, 15, pp.612~632 (2019)
48. von Moltke J, "Recognition of bacteria by inflammasomes", Annu Rev Immunol, 31, pp.73~106 (2013)
49. Skendros P, "Autoinflammation : lessons from the study of familial Mediterranean fever", J Autoimmun, 104, pp.102305~ (2019)
50. Mantovani A, "Interleukin-1 and related cytokines in the regulation of inflammation and immunity", Immunity, 50, pp.778~795 (2019)
51. Zahid A, "Pharmacological inhibitors of the NLRP3 inflammasome", Front Immunol, 10, pp.2538~ (2019)
52. Szekanecz Z, "Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases", Nat Rev Rheumatol, 17, pp.585~595 (2021)
53. Grom AA, "Macrophage activation syndrome in the era of biologic therapy", Nat Rev Rheumatol, 12, pp.259~268 (2016)
54. Choy EH, "Translating IL-6 biology into effective treatments", Nat Rev Rheumatol, 16, pp.335~345 (2020)
55. Bataille R, "Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma", Blood, 86, pp.685~691 (1995)
56. Gabay C, "Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis(ADACTA) : a randomised, double-blind, controlled phase 4 trial", Lancet, 381, pp.1541~1550 (2013)
57. Khanna D, "Tocilizumab in systemic sclerosis : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Respir Med, 8, pp.963~974 (2020)
58. Wallace DJ, "Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus : a phase II dose-ranging randomised controlled trial", Ann Rheum Dis, 76, pp.534~542 (2017)
59. Bettelli E, "Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells", Nature, 441, pp.235~238 (2006)
60. Garbers C, "Interleukin-6 : designing specific therapeutics for a complex cytokine", Nat Rev Drug Discov, 17, pp.395~412 (2018)
61. Heinrich PC, "Interleukin-6-type cytokine signalling through the gp130", Jak, Biochem J, pp.1998, 334[DOI]
62. Taniguchi K, "A gp130-Src-YAP module links inflammation to epithelial regeneration", Nature, 519, pp.57~62 (2015)
63. Yoshida K, "Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders", Proc Natl Acad Sci U S A, 93, pp.407~411 (1996)
64. O’Shea JJ, "Cytokine signaling in 2002 : new surprises in the Jak", Stat pathway, 2002, pp.109(Suppl), S121~S131
65. Cua DJ, "Innate IL-17-producing cells : the sentinels of the immune system", Nat Rev Immunol, 10, pp.479~489 (2010)
66. McGeachy MJ, "The IL-17 family of cytokines in health and disease", Immunity, 50, pp.892~906 (2019)
67. Veldhoen M, "Interleukin 17 is a chief orchestrator of immunity", Nat Immunol, 18, pp.612~621 (2017)
68. Akiyama S, "Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases", J Transl Autoimmun, 4, pp.100104~ (2021)
69. Hirahara K, "Mechanisms underlying helper T-cell plasticity : implications for immune-mediated disease", J Allergy Clin Immunol, 131, pp.1276~1287 (2013)
70. Langrish CL, "IL-23 drives a pathogenic T cell population that induces autoimmune inflammation", J Exp Med, 201, pp.233~240 (2005)
71. Maitra A, "Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression", Proc Natl Acad Sci U S A, 104, pp.7506~7511 (2007)
72. Qian Y, "The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease", Nat Immunol, 8, pp.247~256 (2007)
73. Sieper J, "The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis", Nat Rev Rheumatol, 15, pp.747~757 (2019)
74. Hawkes JE, "Discovery of the IL-23", IL-17 signaling pathway and the treatment of psoriasis, 2018, pp.201, 1605~1613
75. Genovese MC, "A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors", Arthritis Rheumatol, 66, pp.1693~1704 (2014)
76. Oppmann B, "Novel p19protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12", Immunity, 13, pp.715~725 (2000)
77. Gaffen SL, "The IL-23-IL-17 immune axis : from mechanisms to therapeutic testing", Nat Rev Immunol, 14, pp.585~600 (2014)
78. Floss DM, "Insights into IL-23 biology : from structure to function", Cytokine Growth Factor Rev, 26, pp.569~578 (2015)
79. Puccetti P, "Effects of IL-12 and IL-23 on antigen-presenting cells at the interface between innate and adaptive immunity", Crit Rev Immunol, 22, pp.373~390 (2002)
80. Ruiz de Morales JM, "Critical role of interleukin(IL)-17 in inflammatory and immune disorders : an updated review of the evidence focusing in controversies", Autoimmun Rev, 19, pp.102429~ (2020)
81. Thorlacius GE, "An update on the role of type I interferons in systemic lupus erythematosus and Sjögren’s syndrome", Curr Opin Rheumatol, 30, pp.471~481 (2018)
82. Okanoue T, "Side effects of high-dose interferon therapy for chronic hepatitis C", J Hepatol, 25, pp.283~291 (1996)
83. Chasset F, "Targeting interferons and their pathways in systemic lupus erythematosus", Autoimmun Rev, 17, pp.44~52 (2018)
84. Kalunian KC, "A phase II study of the efficacy and safety of rontalizumab(rhuMAb interferon-α)in patients with systemic lupus erythematosus(ROSE)", Ann Rheum Dis, 75, pp.196~202 (2016)
85. Khamashta M, "Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus : a randomised, double-blind, placebo-controlled study", Ann Rheum Dis, 75, pp.1909~1916 (2016)
86. Morand EF, "Trial of anifrolumab in active systemic lupus erythematosus", N Engl J Med, 382, pp.211~221 (2020)
87. Lee DS, "B cell depletion therapies in autoimmune disease : advances and mechanistic insights", Nat Rev Drug Discov, 20, pp.179~199 (2021)
88. Piccio L, "Changes in B-and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis", Arch Neurol, 67, pp.707~714 (2010)
89. Edwards JC, "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis", N Engl J Med, 350, pp.2572~2581 (2004)
90. Ivanov A, "Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells", J Clin Invest, 119, pp.2143~2159 (2009)
91. Crickx E, "Anti-CD20-mediated B-cell depletion in autoimmune diseases : successes, failures and future perspectives", Kidney Int, 97, pp.885~893 (2020)
92. Cree BA, "Inebilizumab for the treatment of neuromyelitis optica spectrum disorder(N-MOmentum) : a double-blind, randomised placebo-controlled phase 2", 3 trial, 2019, pp.394, 1352~1363
93. Parodis I, "Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus", Autoimmun Rev, 16, pp.343~351 (2017)
94. Shi F, "Telitacicept as a BLyS", APRIL dual inhibitor for autoimmune disease, 2021, pp.43, 666~673
95. Seongju Jeong, "Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy", Immune Network, 20(1), pp.1~20 (2020), 대한면역학회[DOI]
96. Edner NM, "Targeting co-stimulatory molecules in autoimmune disease", Nat Rev Drug Discov, 19, pp.860~883 (2020)
97. Esensten JH, "CD28 costimulation : from mechanism to therapy", Immunity, 44, pp.973~988 (2016)
98. Rowshanravan B, "CTLA-4 : a moving target in immunotherapy", Blood, 131, pp.58~67 (2018)
99. Liu M, "A review on applications of abatacept in systemic rheumatic diseases", Int Immunopharmacol, 96, pp.107612~ (2021)
100. Larsen CP, "Rational development of LEA29Y(belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties", Am J Transplant, 5, pp.443~453 (2005)
101. Douthwaite J, "A CD80-biased CTLA4-Ig fusion protein with superior in vivo efficacy by simultaneous engineering of affinity, selectivity, stability, and FcRn binding", J Immunol, 198, pp.528~537 (2017)
102. Huber M, "Should belatacept be the centrepiece of renal transplantation", Nephrol Dial Transplant, 31, pp.1995~2002 (2016)
103. Caux C, "Activation of human dendritic cells through CD40 cross-linking", J Exp Med, 180, pp.1263~1272 (1994)
104. van Kooten C, "CD40-CD40 ligand", J Leukoc Biol, 67, pp.2~17 (2000)
105. Foy TM, "gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory", J Exp Med, 180, pp.157~163 (1994)
106. Fisher BA, "Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren’s syndrome : a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study", Lancet Rheumatol, 2, pp.e142~e152 (2020)
107. Villarino AV, "Mechanisms and consequences of Jak-STAT signaling in the immune system", Nat Immunol, 18, pp.374~384 (2017)
108. McLornan DP, "Current and future status of JAK inhibitors", Lancet, 398, pp.803~816 (2021)
109. Taylor PC, "Baricitinib versus placebo or adalimumab in rheumatoid arthritis", N Engl J Med, 376, pp.652~662 (2017)
110. Papp K, "Phase 2trial of selective tyrosine kinase 2 inhibition in psoriasis", N Engl J Med, 379, pp.1313~1321 (2018)
111. Montalban X, "Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis", N Engl J Med, 380, pp.2406~2417 (2019)
112. Reich DS, "Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis : a phase 2b, randomised, double-blind, placebo-controlled trial", Lancet Neurol, 20, pp.729~738 (2021)
113. "FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions"[URL]
114. June CH, "CAR T cell immunotherapy for human cancer", Science, 359, pp.1361~1365 (2018)
115. Rafiq S, "Engineering strategies to overcome the current roadblocks in CAR T cell therapy", Nat Rev Clin Oncol, 17, pp.147~167 (2020)
116. Mougiakakos D, "CD19-targeted CAR T cells in refractory systemic lupus erythematosus", N Engl J Med, 385, pp.567~569 (2021)
117. Orvain C, "Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases?", Arthritis Rheumatol, 73, pp.1954~1965 (2021)
118. Brudno JN, "Recent advances in CAR T-cell toxicity : mechanisms, manifestations and management", Blood Rev, 34, pp.45~55 (2019)
119. Spolski R, "Biology and regulation of IL-2 : from molecular mechanisms to human therapy", Nat Rev Immunol, 18, pp.648~659 (2018)
120. Kolios AG, "Interleukin-2 and regulatory T cells in rheumatic diseases", Nat Rev Rheumatol, 17, pp.749~766 (2021)
121. Liao W, "Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy", Immunity, 38, pp.13~25 (2013)
122. Churlaud G, "Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer", Clin Immunol, 151, pp.114~126 (2014)
123. Pinheiro-Rosa N, "Oral tolerance as antigen-specific immunotherapy", Immunother Adv, 1, pp.ltab017~ (2021)
124. Mowat AM, "Anatomical basis of tolerance and immunity to intestinal antigens", Nat Rev Immunol, 3, pp.331~341 (2003)
125. Faria AM, "Oral tolerance : therapeutic implications for autoimmune diseases", Clin Dev Immunol, 13, pp.143~157 (2006)
126. Ring S, "Targeting of autoantigens to DEC205+ dendritic cells in vivo suppresses experimental allergic encephalomyelitis in mice", J Immunol, 191, pp.2938~2947 (2013)
127. Getts DR, "Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis", Nat Biotechnol, 30, pp.1217~1224 (2012)
128. Moorman CD, "Emerging therapeutics for immune tolerance : tolerogenic vaccines, T cell therapy, and IL-2 therapy", Front Immunol, 12, pp.657768~ (2021)
129. Freedman MS, "A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS", Neurology, 77, pp.1551~1560 (2011)
130. Krienke C, "A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis", Science, 371, pp.145~153 (2021)

관련 논문AI추천